PD-1抑制剂治疗伴肺转移的基底细胞癌
本文报道一例组织学复杂的病例,初始成分被分类为基底鳞状细胞癌(bSCC)伴肺转移,接受PD-1抑制剂西米普利单抗治疗后出现影像学和临床缓解;重新检查肺活检并结合细胞角蛋白14、细胞角蛋白17和BerEp4免疫组化染色,揭示为基底细胞癌(BCC)的组织病理学模式,与患者5年多前面部皮肤原发肿瘤的手术切除标本分析一致。
要点
- BCC与bSCC在临床和组织学上鉴别困难,BCC转移极罕见而bSCC易发生远处转移。
- 不可手术的转移性病变中,PD-1抑制剂可能对两者均为有效选择。
- 本例经西米普利单抗治疗后达到影像学和临床缓解,重新活检修正诊断为BCC。
核心结论
- PD-1抑制剂西米普利单抗治疗使该例伴肺转移的复杂组织学肿瘤获得影像学和临床缓解。
- 重新评估肺活检并结合免疫组化染色,将诊断修正为BCC,与5年多前手术的面部原发肿瘤一致。
研究设计与样本
- 个案报道,描述一例组织学复杂的肿瘤患者,初始分类为bSCC伴肺转移,接受PD-1抑制剂西米普利单抗治疗,后重新检查肺活检并行免疫组化染色。
主要发现
- 肺活检重新检查采用常规组织形态学并结合细胞角蛋白14、细胞角蛋白17和BerEp4免疫组化染色,显示BCC的组织病理学模式。
- 该结果与患者5年多前面部皮肤原发肿瘤手术标本的类似分析一致。
- 西米普利单抗治疗后出现影像学和临床缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal cell carcinoma (BCC) may be challenging to differentiate from basaloid squamous cell carcinoma (bSCC), both clinically and histologically. BCC constitutes one of the most common tumours and metastatic behaviour is extremely rare. In contrast, bSCC is a rare entity with an increased propensity for distant metastasis. If these conditions develop into inoperable metastatic disease, the therapeutic alternatives are different, but the use of PD-1 inhibitors may be a valid option for both. Here, we report a case with complex histology with a component initially classified as bSCC with lung metastases and treated with the PD-1 inhibitor cemiplimab resulting in radiological and clinical responses. Re-examination of the lung biopsy using routine histomorphology in combination with immunohistochemical staining for cytokeratin 14, cytokeratin17 and BerEp4 has, however, revealed a histopathological pattern of BCC, which is in concordance with a similar analysis of the cutaneous primary tumour in the face that the patient underwent surgery for more than 5 years earlier.
引用
- Johansson I, Levin M, Akyürek LM, et al. PD-1 inhibitor therapy of basal cell carcinoma with pulmonary metastasis. J Eur Acad Dermatol Venereol. 2022. PMID: 34855248. doi:10.1111/jdv.17530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。